On April 16, 2025, the Company's stockholders approved a reverse stock split of the Company's Common Stock at a ratio in the range of 5-for-one to 25-for-one, with such ratio to be determined by the Company's Board of Directors. The Reverse Stock Split is expected to be effective before market open on July 1, 2025 (the "Effective Time") and the Company's Common Stock will begin trading on a split-adjusted basis on the NYSE American under the name "Pelthos Therapeutics Inc." at the market open on July 2, 2025.
At the Effective Time, every 10 issued and outstanding shares of the Company's Common Stock will be converted into one share of the Company's Common Stock. Once effective, the Reverse Stock Split will reduce the number of issued and outstanding shares of Common Stock from approximately 6,485,007 to approximately 648,501 shares, notwithstanding reconciliation of fractional shares.
Each stockholder's percentage ownership interest in the Company will remain unchanged as a result of the Reverse Stock Split. No fractional shares shall be issued in connection with the Reverse Stock Split, and any fractional shares resulting from the Reverse Stock Split will be rounded up at the participant level with The Depository Trust Company. Each certificate that immediately prior to the Effective Time represented shares of Common Stock shall ...